Fortress Biotech, Inc. FBIO
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Fortress Biotech, Inc. (FBIO) is a healthcare company listed in the US with a market value of about $63M. In the twelve months to September 30, 2026 it had revenue of $70M and net income of $92M, a net margin of 131.2%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is value (3/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.7, 5-year revenue growth of 7% a year, a 5-year average ROIC of -88%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 439% above the current price.
About Fortress Biotech
Fortress Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $863000 in 2015 to $63M in 2025, growth of about 53.6% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 371% over three years (dilution for shareholders). It spends 19% of revenue on research and development.
Score: 1.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Pays a dividend
- Dividend 3 years in a row
Checks not passed
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70M | $63M | $58M | $85M | $76M | $69M | $46M | $37M | $27M | $188M | $16M |
| Net income | $92M | $7M | -$46M | -$61M | -$87M | -$65M | -$47M | -$40M | -$84M | -$67M | -$55M |
| Free cash flow | — | — | -$80M | -$128M | -$182M | -$121M | -$86M | -$97M | -$106M | -$82M | -$52M |
| EPS (diluted) | $2.72 | $-0.07 | $-2.69 | $-8.47 | $-15.97 | $-11.85 | $-9.75 | $-10.95 | $-29.10 | $-24.15 | $-20.70 |
| Net margin | 131.2% | 10.8% | -79.8% | -71.8% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.6% | -334.3% |
| ROIC | — | -58.9% | -88.9% | -107.9% | -100.2% | -84.9% | -42.5% | -81.7% | -139.1% | -59.1% | -95.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $5.00, 166% above the current price; targets range from $5.00 to $5.00; the consensus rating is “none”; expected EPS is $2.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Fortress Biotech’s P/E ratio?
About 0.7, based on the last twelve months of diluted earnings per share.
Is Fortress Biotech stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 439% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Fortress Biotech pay a dividend?
Not currently.
Is Fortress Biotech a good stock to buy?
We do not give buy or sell advice. Fortress Biotech scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.